A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)

Trial Profile

A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Dianhydrogalactitol (Primary) ; Carboplatin; Lomustine; Temozolomide
  • Indications Glioblastoma; Gliosarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms STAR-3
  • Sponsors Del Mar Pharmaceuticals
  • Most Recent Events

    • 06 Sep 2017 According to a DelMar Pharmaceuticals media release, update from the study will be presented at the 19th Annual Rodman & Renshaw Global Investment Conference 2017.
    • 31 Jul 2017 Status changed to recruiting.
    • 18 Jul 2017 According to a DelMar Pharmaceuticals media release, Dr. Laszlo Mechtler will serve as principal investigator for the STAR-3 trial at Dent Neurological Institute.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top